EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

EGFR stands for epidermal growth factor receptor. It is a protein on the surface of cells that tells them to grow. In some non-small cell lung cancers, the EGFR gene is mutated and the receptor gets stuck in the on position. This happens most often in adenocarcinoma. That single change drives the cancer. It is also what makes the cancer a target.

The tumor picks up this mutation. You did not inherit it, and you cannot pass it on. EGFR-mutated lung cancer is more common in people who never smoked or smoked lightly, in women, and in people of East Asian descent. But it occurs in every group.

Two changes are called classical or sensitizing mutations: an exon 19 deletion and the L858R change in exon 21. They respond well to EGFR pills. Exon 20 insertions behave differently, and are covered below.

Biomarker testing looks at tumor tissue, sometimes paired with a blood test for circulating tumor DNA. It looks for EGFR and other targets such as ALK, ROS1, KRAS, BRAF, RET, MET and HER2. Results usually take one to three weeks.

Unless you are very unwell, waiting is generally worth it. Starting the wrong treatment first can narrow your later choices. Ask which test was ordered. Ask whether it detects exon 20 insertions, and when results are due.

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor. You take it as a daily pill. It reaches the brain better than older drugs in this class. That matters, because EGFR-mutated lung cancer often spreads there.

It is used in several settings:

• Advanced or metastatic disease, as first-line treatment, and in some cases combined with chemotherapy.
• After surgery, as adjuvant treatment for resected stage IB to IIIA disease, based on the ADAURA trial.
• After chemoradiation, for unresectable stage III disease, based on the LAURA trial.

Older EGFR inhibitors are still used in some situations. These include erlotinib, gefitinib, afatinib and dacomitinib. Amivantamab with lazertinib is another approved first-line option. Across this drug class, typical side effects are rash, acne-like skin changes, diarrhea, dry skin and nail changes. Most can be managed. Reporting them early usually keeps you on treatment.

If your report says EGFR exon 20 insertion, the standard EGFR pills generally do not work well. The extra genetic material changes the shape of the binding pocket, so the drug cannot hold on.

Treatment for these tumors has followed its own path. Amivantamab is a bispecific antibody. It is approved with chemotherapy as first-line treatment, and on its own after chemotherapy. This is why the exact variant on your report matters, not just the words "EGFR positive."

People often miss this point, and it is worth understanding.

Immune checkpoint inhibitors have changed treatment for many lung cancers. They include pembrolizumab, nivolumab and atezolizumab. But given on their own in EGFR-mutated disease, they work poorly. Response rates are low even when the PD-L1 score is high. A high PD-L1 number does not predict benefit in this group the way it does in EGFR-normal cancer. So guidelines send people with sensitizing EGFR mutations to targeted therapy first.

There is a safety angle too. In trials, giving a checkpoint inhibitor close to an EGFR inhibitor has caused serious lung and liver inflammation. So the order and timing of these drugs is handled with care.

If immunotherapy alone is suggested because of a high PD-L1 score, ask how that fits with your EGFR result. That is a fair question.

Most people eventually develop resistance. When scans change, repeat testing of tissue or blood can show why. It may find a new EGFR change such as C797S, or MET amplification, or a shift in the cancer's cell type.

Next steps often include chemotherapy-based combinations, antibody-drug conjugates, or a trial matched to the resistance mechanism. Asking about trials at each turning point is normal and expected. It is not a sign that options have run out.

The pills are easy to take at home, which makes it easy to sit on a problem. A few signs should not wait.

• Call 911 or go to an emergency department if breathing suddenly gets harder, you have chest pain, or your heart pounds or races and you feel lightheaded or close to fainting. MedlinePlus lists these among the osimertinib effects needing emergency care. Swollen ankles or feet with breathlessness belong here too.
• Contact your cancer team immediately if you have a fever of 100.4°F (38°C) or higher. This is a medical emergency on chemotherapy, with or without amivantamab, and it is treated the same way on an EGFR pill alone, since these drugs can also drop the white cells that fight infection. CDC treats fever during chemotherapy as an emergency. Ring the team at any hour, day or night. If you cannot get through fast, go to an emergency department and say at the desk that you are on treatment for lung cancer.
• Call your care team the same day if you have a cough that is new or getting worse. Lung inflammation from an EGFR inhibitor is uncommon but serious, and it is treated by stopping the drug early rather than waiting it out.
• Call your care team within a day or two if the skin rash blisters or peels, your eyes turn red, watery, painful or sensitive to light, or your vision changes. Diarrhea that is not settling with what you were given also fits here. Do not simply stop the tablet on your own. Tell the team, because the usual fix is a short hold or a dose change, not the end of treatment.

• FDA: osimertinib for unresectable stage III NSCLC after chemoradiation
• FDA: amivantamab-vmjw for EGFR exon 20 insertion NSCLC
• NCI: Osimertinib Improves Survival in Lung Cancer (ADAURA)
• NCI drug information: osimertinib
• Review: immune checkpoint inhibitor therapy in EGFR-mutated NSCLC
• MedlinePlus drug information: osimertinib
• CDC — Fever During Chemotherapy Is an Emergency